Target intelligence / Profile preview

Myomesin-2 (MYOM2)

Target
MYOM2
Molecular classification
Structural protein, Sarcomeric protein, Cytoskeletal protein, Immunoglobulin superfamily domain containing, Fibronectin type III domain containing
01

Overview

Myomesin-2 (MYOM2) is a large structural protein predominantly expressed in adult cardiac and fast skeletal muscle, where it localizes at the M-band of sarcomeres and provides mechanical stability essential for contraction[1][2][3][5]. It plays a key role in cross-linking thick filaments by binding to myosin, titin, and other sarcomeric proteins, forming part of the cytoskeletal scaffold that ensures the structural and metabolic integrity of muscle fibers[1][5]. MYOM2 also interacts in an isoform-specific manner with muscle-type creatine kinase, which is crucial for localized ATP generation required during muscle contraction[1]. Alterations in MYOM2 expression or structure have been implicated in various muscle and cardiovascular diseases, though it is not a conventional therapeutic target such as a receptor or enzyme[2][3][5]. Its encoded protein consists of multiple immunoglobulin-like and fibronectin type III domains. MYOM2 is essential for normal muscle function but is primarily characterized as a structural, rather than a druggable or therapeutic, molecular target.

Other names
165 kDa connectin-associated protein165 kDa titin-associated proteinM-proteinTTNAPM-band proteinmyomesin family member 2titin-associated protein165 kD
02

Biological functions

Structural constituent of muscleStabilization of sarcomere M-bandCross-linking thick filamentsRegulation of muscle contraction and energy metabolism
03

Disease associations

Cardiovascular disease (e.g., cardiomyopathies)Parkinson diseaseMultiple sclerosisAlzheimer diseaseRheumatic feverNecrotizing fasciitisOther associations reported in rare skin and genetic syndromes
04

Safety considerations

Targeting or perturbing MYOM2 could potentially compromise muscle, especially cardiac muscle, integrity and function due to its essential structural role.
05

Biomarkers

Related myomesins may be explored as muscle damage markers, but no consensus as biomarker for MYOM2 specifically.

Beyond the preview

Go deeper on Myomesin-2 (MYOM2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Myomesin-2 (MYOM2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call